1887
Research article Open Access
Like 0

Abstract

We estimated the direct, indirect and total effects of the 13-valent pneumococcal conjugate vaccine (PCV13) on invasive pneumococcal disease (IPD) in children. A population-based cohort study followed children aged between 2.5 and 59 months between 2001 and 2014 in Navarra, Spain. IPD incidence was compared by PCV status and period. All cases diagnosed from July 2010 to December 2014 and eight matched controls per case were analysed to estimate the adjusted direct effect of PCV13. A total of 120,980 children were followed and 206 IPD cases were detected. Compared with unvaccinated children in the baseline period (2001–2004), overall IPD incidence in 2011–2014 (76% average PCV coverage) declined equally in vaccinated (total effect: 76%; hazard ratio (HR): 0.24; 95% confidence interval (CI): 0.14–0.40) and unvaccinated children (indirect effect: 78%; HR: 0.22; 95% CI: 0.09–0.55). IPD incidence from non-PCV13 serotypes increased among vaccinated children (HR: 2.84; 95% CI: 1.02–7.88). The direct effect of one or more doses of PCV13 against vaccine serotypes was 95% (odds ratio: 0.05; 95% CI: 0.01–0.55). PCV13 was highly effective in preventing vaccine-serotype IPD. The results suggest substantial and similar population-level vaccine benefits in vaccinated and unvaccinated children through strong total and indirect effects.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2016.21.14.30186
2016-04-07
2017-11-23
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2016.21.14.30186
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/21/14/eurosurv-21-30186-3.html?itemId=/content/10.2807/1560-7917.ES.2016.21.14.30186&mimeType=html&fmt=ahah

References

  1. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495-502. https://doi.org/10.1016/S0140-6736(06)69637-2  PMID: 17071283 
  2. Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreño RA, Nohynek H, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;7(4):CD004977. PMID: 19821336 
  3. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378(9807):1962-73. https://doi.org/10.1016/S0140-6736(10)62225-8  PMID: 21492929 
  4. Rozenbaum MH, Boersma C, Postma MJ, Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines. 2011;10(2):187-99. https://doi.org/10.1586/erv.10.163  PMID: 21332268 
  5. World Health Organization (WHO). Recommendations for the production and control of pneumococcal conjugate vaccines. Technical Report Series 927, fifty-fourth report. Annex 2. Geneva: WHO; 2005. Available from: http://apps.who.int/medicinedocs/documents/s16102e/s16102e.pdf
  6. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29(49):9127-31. https://doi.org/10.1016/j.vaccine.2011.09.112  PMID: 21983361 
  7. Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839-46. https://doi.org/10.1016/S1473-3099(14)70822-9  PMID: 25042756 
  8. Deceuninck G, De Serres G, Boulianne N, Lefebvre B, De Wals P. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine. 2015;33(23):2684-9. https://doi.org/10.1016/j.vaccine.2015.04.005  PMID: 25887086 
  9. Davis SM, Deloria-Knoll M, Kassa HT, O’Brien KL. Impact of pneumococcal conjugate vaccines on nasopharyngeal carriage and invasive disease among unvaccinated people: review of evidence on indirect effects. Vaccine. 2013;32(1):133-45. https://doi.org/10.1016/j.vaccine.2013.05.005  PMID: 23684824 
  10. Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066-73. https://doi.org/10.1093/cid/ciu524  PMID: 25034421 
  11. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301-9. https://doi.org/10.1016/S1473-3099(14)71081-3  PMID: 25656600 
  12. Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535-43. https://doi.org/10.1016/S1473-3099(15)70044-7  PMID: 25801458 
  13. Halloran ME, Struchiner CJ, Longini IM Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol. 1997;146(10):789-803. https://doi.org/10.1093/oxfordjournals.aje.a009196  PMID: 9384199 
  14. Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine. 2013;31(48):5634-42. https://doi.org/10.1016/j.vaccine.2013.07.006  PMID: 23856332 
  15. Instituto de Salud Pública de Navarra [Public Health Institute of Navarra]. Instrucciones sobre la vacunación de adultos y en situaciones clínicas especiales [Instructions on vaccination of adults and patients in special clinical situations]. Boletín Informativo. 2013;72:1-3. Spanish. [Accessed July 2015]. Available from: http://www.navarra.es/NR/rdonlyres/AECCD760-AB2A-4841-818A-FA53478FD6DC/255921/BOL72INT.pdf
  16. Moreno-Pérez D, Alvarez García FJ, Aristegui Fernández J, Barrio Corrales F, Cilleruelo Ortega MJ, Corretger Rauet JM, et al. Immunization schedule of the Spanish Association of Pediatrics: 2012 recommendations. An Pediatr (Barc). 2012;76(1):43.e1-23. https://doi.org/10.1016/j.anpedi.2011.10.008  PMID: 22177960 
  17. Guevara M, Ezpeleta C, Gil-Setas A, Torroba L, Beristain X, Aguinaga A, et al. Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001-2013. Vaccine. 2014;32(22):2553-62. https://doi.org/10.1016/j.vaccine.2014.03.054  PMID: 24674661 
  18. Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, et al. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis. 2014;210(7):1001-11. https://doi.org/10.1093/infdis/jiu213  PMID: 24719477 
  19. Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31(52):6232-8. https://doi.org/10.1016/j.vaccine.2013.10.032  PMID: 24176490 
  20. Aguiar SI, Brito MJ, Horacio AN, Lopes JP, Ramirez M, Melo-Cristino J, et al. Decreasing incidence and changes in serotype distribution of invasive pneumococcal disease in persons aged under 18 years since introduction of 10-valent and 13-valent conjugate vaccines in Portugal, July 2008 to June 2012. Euro Surveill. 2014;19(12):20750. https://doi.org/10.2807/1560-7917.ES2014.19.12.20750  PMID: 24698140 
  21. Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015;33(2):359-66. https://doi.org/10.1016/j.vaccine.2014.11.011  PMID: 25448105 
  22. Instituto Nacional de Estadística, España [National Statistics Institute, Spain]. INEbase. Estadística del Padrón Continuo. Datos nacionales, por CCAA y por provincias. [Continuous Register Statistics. National level data, by autonomous community and province] [Accessed July 2015]. Available from: http://www.ine.es/jaxi/menu.do?type=pcaxis&path=/t20/e245/&file=inebase.
  23. Aguilar I, Reyes M, Martínez-Baz I, Guevara M, Albeniz E, Belza M, et al. Use of the vaccination register to evaluate influenza vaccine coverage in seniors in the 2010/11 influenza season, Navarre, Spain. Euro Surveill. 2012;17(17):20154. PMID: 22551499 
  24. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297(16):1784-92. https://doi.org/10.1001/jama.297.16.1784  PMID: 17456820 
  25. Guevara M, Barricarte A, Gil-Setas A, García-Irure JJ, Beristain X, Torroba L, et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect. 2009;15(11):1013-9. https://doi.org/10.1111/j.1469-0691.2009.02904.x  PMID: 19673968 
  26. van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Keijzers WC, Bogaert D, et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA. 2010;304(10):1099-106. https://doi.org/10.1001/jama.2010.1290  PMID: 20823436 
  27. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517. https://doi.org/10.1371/journal.pmed.1001517  PMID: 24086113 
  28. van der Linden M, Perniciaro S, Imöhl M. Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era. BMC Infect Dis. 2015;15(1):207. https://doi.org/10.1186/s12879-015-0941-9  PMID: 25940580 
  29. Nunes MC, Madhi SA. Review on the immunogenicity and safety of PCV-13 in infants and toddlers. Expert Rev Vaccines. 2011;10(7):951-80. https://doi.org/10.1586/erv.11.76  PMID: 21806394 
  30. Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts’ children. Pediatr Infect Dis J. 2014;33(5):504-10. https://doi.org/10.1097/INF.0000000000000279  PMID: 24670957 
/content/10.2807/1560-7917.ES.2016.21.14.30186
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error